- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02342717
Relativ biotilgængelighed af en enkelt oral dosis af BI 425809, når den administreres alene eller i kombination med flere orale doser af itraconazol hos raske mandlige forsøgspersoner
Relativ biotilgængelighed af en enkelt oral dosis af BI 425809, når den administreres alene eller i kombination med flere orale doser af itraconazol hos raske mandlige forsøgspersoner (et åbent, to-perioders forsøg med fast sekvens)
To investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI 425809 in healthy male subjects
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Biberach, Tyskland
- 1346.10.1 Boehringer Ingelheim Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Healthy male subjects according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
- Age of 18 to 50 years (incl.)
- Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
Exclusion criteria:
- Any finding in the medical examination (including BP, PR or ECG) is deviating from normal and judged as clinically relevant by the investigator
- Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- Any evidence of a concomitant disease judged as clinically relevant by the investigator
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
- Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- History of relevant orthostatic hypotension, fainting spells, or blackouts
- Chronic or relevant acute infections
- History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
- Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 halflives of the respective drug prior to administration of trial medication
- Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial or that might prolong the QT/QTc interval
- Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication
- Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- Inability to refrain from smoking on specified trial days
- Alcohol abuse (consumption of more than 30 g per day)
- Drug abuse or positive drug screening
- Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
- Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
- Inability to comply with dietary regimen of trial site
- A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
- A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
- Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
- Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two month after the trial completion. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive for at least two month prior trial participation)
- Known fructose intolerance, glucose-galactose malabsorption, or saccharose-isomaltase deficiency
- History of relevant liver diseases such as disturbance of liver function, jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver tumours
- Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening examination
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment R (BI 425809 alone) then Treatment T (BI 425809 + Itraconazole)
Treatment R: Subjects were administered single dose of 25 milligram (mg) BI 425809 (tablet) on Day 1. Treatment was administered orally with 240 mL of water after administration of a standardised breakfast. Treatment T: Subjects underwent 10 days of itraconazole (capsules) treatment (first day 200 mg itraconazole twice daily, followed by 9 days 200 mg itraconazole once daily) combined with a single dose of 25 mg BI 425809 (tablet) on the fourth day of the itraconazole treatment (1 h after the itraconazole administration). Treatments were administered orally with 240 mL of water after administration of a standardised breakfast or dinner. The BI 425809 single doses of treatments R and T were separated by a washout period of at least 16 days. |
single dose BI 425809 tablet
Andre navne:
multiple doses of Itraconazole capsules |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 167 h (AUC0-167)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
AUC0-167 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 167 h); Detailed sampling time points: -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration |
Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
|
Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
Cmax (maximum measured concentration of the analyte in plasma); Detailed sampling time points: -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration |
Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Detailed sampling time points: -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration |
Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Boehringer Ingelheim, Boehringer Ingelheim
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 1346.10
- 2014-004855-29 (EudraCT nummer: EudraCT)
- 2014 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization).
For more details refer to:
https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .